Development and Evaluation of Mobile App Based Myofunctional Therapy Program (MabMTP) in Obstructive Sleep Apnea: An Intervention Mapping Approach

Development and Effectiveness of a Mobile app-Based Myofunctional Therapy Program for Improving Obstructive Sleep Apnea

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0008472

Enrollment

Registered

2023-05-26

Start date

2023-04-26

Completion date

Unknown

Last updated

2024-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Behavioral : In this study, a mobile app-based myofunctional therapy program is applied to the experimental group for 12 weeks, and the comparative group is provided with one upper airway muscle funct

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion Criteria Individuals who understand the purpose of this study and agree to participate. Individuals diagnosed with obstructive sleep apnea by a sleep specialist based on the results of a sleep study, and who have been recommended myofunctional therapy by the sleep specialist. Adults aged 18 years or older. Individuals with no communication disabilities. Individuals who can attach the sleep study device to at least one finger and wrist. Individuals who have a mobile phone capable of running the mobile app (Android or iOS) and can use it without assistance.

Exclusion criteria

Exclusion criteria: Exclusion Criteria Individuals with severe nasal obstruction or facial deformities confirmed by imaging studies. Individuals whom the sleep specialist determines to be unable to perform myofunctional therapy due to musculoskeletal disorders. Individuals with autonomic nervous system dysfunction, peripheral neuropathy, vascular disease, heart disease, or lung disease. Individuals taking medications that may affect peripheral arterial tone (adrenergic blockers). Types of adrenergic blockers: Tolazoline, Trazodone, Phenoxybenzamine, Phentolamine, Doxazosin, Silodosin, Alfuzosin, Tamsulosin, Terazosin, Prazosin, Mirtazapine, Atipamezole, Yohimbine, Idazoxan, Labetalol, Carvedilol. (Note: Criteria 3 and 4 are exclusion criteria to prevent errors that may occur when using portable sleep study devices.)

Design outcomes

Primary

Measure	Time frame
apnea-hypopnea index	—

Secondary

Measure	Time frame
daytime sleepiness, sleep quality, self-efficacy, outcome expectancy, intervention adherence, lowest spo2, snoring rate	—

Countries

Korea, Republic of

Contacts

Public ContactMINEUN CHO

Pusan National University

cme4948@nate.com+82-51-510-8339

Outcome results